The report provides a detailed analysis essential for establishing a Trifluridine production plant. It encompasses all critical aspects necessary for Trifluridine production, including the cost of Trifluridine production, Trifluridine plant cost, Trifluridine production costs, and the overall Trifluridine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Trifluridine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Trifluridine is a fluorinated pyrimidine nucleoside antiviral and antineoplastic agent. It stops viral or cancer cell DNA replication by combining with DNA that blocks thymidylate synthase. This disrupts protein synthesis and triggers cell death, and its oral bioavailability is improved by using it in combination form. It is used in ophthalmic eye drops to treat primary keratoconjunctivitis and recurrent epithelial keratitis from herpes simplex virus. It is also used in vaccinia eye infections and stops viral spread to promote healing faster than alternatives like idoxuridine.
It is utilised in oncology as a third-line chemotherapy alone or with bevacizumab for refractory metastatic colorectal cancer. Its common side effects include temporary burning or stinging upon application, eye irritation or redness, swollen eyelids, itching, blurred vision, etc.
The market for Trifluridine is driven by growing incidences of herpes simplex virus (HSV) eye infections and refractory metastatic colorectal and gastric cancers. Its approval as a third-line therapy, ageing populations increasing ocular demands, and rising global cancer prevalence (e.g., colorectal cases) fuel its market.
Its use in combination regimens with other chemotherapies like 5-FU/irinotecan expands. Its North American and European market leads because of advanced oncology infrastructure and high diagnosis rates, while Asia-Pacific grows fastest from healthcare access improvements and antiviral needs. The industrial Trifluridine procurement is influenced by high-cost versions versus generic ophthalmic drops, along with strict regulatory compliance for API purity/stability in eye solutions and oral combos.
Raw Material for Trifluridine Production
According to the Trifluridine production plant project report, the key raw materials used in the production of Trifluridine include 2'-Deoxyuridine-(Sodium Trifluoromethanesulfinate)-(t-Butyl Hydroperoxide).
Production Process of Trifluridine
The extensive Trifluridine production cost report consists of the following major industrial production process:
- From 2'-Deoxyuridine and Sodium Trifluoromethanesulfinate: The production of Trifluridine synthesis involves a reaction between 2'-deoxyuridine and sodium trifluoromethanesulfinate. The reaction takes place in purified water under a nitrogen stream for protection. After initial stirring, t-butyl hydroperoxide is added dropwise and stirred until reaction completion. The mixture is then cooled to room temperature and extracted with ethyl acetate, and the combined extract is concentrated to get Trifluridine as the final product.
Trifluridine is a white crystalline powder with the molecular formula C10H11F3N2O5 and a molecular weight of around 296.2 g/mol. It has a melting point of 190-193 degree Celsius and a density of about 1.4365 g/cm³ (estimated). It is freely soluble in methanol and acetone, soluble in water (up to 14 mg/mL), ethanol, dilute hydrochloric acid, and dilute sodium hydroxide. It is sparingly soluble in isopropyl alcohol and acetonitrile, slightly soluble in diethyl ether, and very slightly soluble in isopropyl ether. Its pKa is around 7.85, and it should be stored at 2-8 degree Celsius to maintain stability. The structure includes trifluoromethyl and pyrimidine groups, which contribute to its antiviral and antineoplastic properties.